1. Home
  2. OGG vs ANNX Comparison

OGG vs ANNX Comparison

Compare OGG & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Osisko Gold Group Inc. Common Shares

OGG

Osisko Gold Group Inc. Common Shares

N/A

Current Price

$2.31

Market Cap

871.6M

Sector

N/A

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

N/A

Current Price

$3.97

Market Cap

726.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OGG
ANNX
Founded
N/A
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
871.6M
726.1M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
OGG
ANNX
Price
$2.31
$3.97
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
1.8M
★ 3.5M
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.22
$2.54
52 Week High
$3.30
$7.18

Technical Indicators

Market Signals
Indicator
OGG
ANNX
Relative Strength Index (RSI) 32.75 49.92
Support Level N/A $3.71
Resistance Level $2.98 $4.07
Average True Range (ATR) 0.12 0.26
MACD -0.02 0.05
Stochastic Oscillator 19.60 73.38

Price Performance

Historical Comparison
OGG
ANNX

About OGG Osisko Gold Group Inc. Common Shares

Osisko Gold Group Inc is a continental North American gold development company focused on past producing mining camps with district-scale potential. The company's objective is to become an intermediate gold producer through the development of its flagship, Cariboo Gold Project, located in central British Columbia, Canada. Its project portfolio also includes the Tintic Project in the East Tintic mining district of Utah, United States.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: